Mainz Biomed (NASDAQ:MYNZ – Free Report)’s stock is going to reverse split on Tuesday, December 3rd. The 1-40 reverse split was announced on Friday, November 29th. The number of shares owned by shareholders will be adjusted after the market closes on Monday, December 2nd.
Mainz Biomed Price Performance
NASDAQ MYNZ traded down $0.04 during midday trading on Friday, hitting $0.22. The company had a trading volume of 7,094,717 shares, compared to its average volume of 1,350,238. The firm has a 50-day moving average price of $0.26 and a 200-day moving average price of $0.39. Mainz Biomed has a twelve month low of $0.19 and a twelve month high of $1.79.
Wall Street Analyst Weigh In
Separately, HC Wainwright cut Mainz Biomed from a “buy” rating to a “neutral” rating in a report on Monday.
Mainz Biomed Company Profile
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
Read More
- Five stocks we like better than Mainz Biomed
- The Significance of Brokerage Rankings in Stock Selection
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- Want to Profit on the Downtrend? Downtrends, Explained.
- 3 Penny Stocks Ready to Break Out in 2025
- Why is the Ex-Dividend Date Significant to Investors?
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
